Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia

As part of a series of invited commentaries in Clinical Microbiology and Infection [ [1] Leibovici L. Paul M. Doernberg S.B. Which randomized controlled trial do we need?. Clin Microbiol Infect. 2022; 28: 1525https://doi.org/10.1016/j.cmi.2022.10.008 Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar ], we propose a clinical trial to evaluate whether highly sensitive next-generation sequencing platforms that quantify pathogen genetic material in plasma can serve as a surrogate for clinical response to therapy, individualize antibiotic therapy in patients with Staphylococcus aureus bacteraemia (SAB), and, ultimately, improve patient outcomes.